Navigation Links
Herceptin for Early Stage Breast cancer

Herceptin is a breast cancer drug which is approved for treatment to breast cancer patients with Her-2/neu positive gene, more than 25% of women with breast cancer// produce this Her-2 protein in their blood which makes their breast cancer very aggressive and resist chemotherapy and Tamoxifen therapy (anti-estrogen therapies). The Drug Herceptin is a humanized monoclonal antibody prepared for treating Her-2 positive patients but the drug is very costly and the Herceptin treatment is to be given for 1 year.

Herceptin is approved for late stage breast cancer treatment but a new study conducted by Breast Cancer International Research Group (BCIRG) have found that Herceptin is also very effective in treating early stage breast cancer disapproving early reports that the drug Herceptin is not effective in treating early stage breast cancer reported by The Lancet on November 10th.

Professor Dennis Slamon and his colleagues, University of California, Los Angeles, conducted a BCIRG trial and found that Herceptin supplemented with Chemotherapy in early stage breast cancer patients to Her-2/neu positive patients found better prognosis compared to chemotherapy treatment alone. The results of the trial had shown the benefits of Herceptin drug also in the treatment of early stage breast cancer.

Page: 1

Related medicine news :

1. Nurse wins her case over use of Herceptin for her Breast cancer
2. Drug Herceptin To Be Recommended To All Breast Cancer Patients
3. Herceptin Is A Possible Cure For Breast Cancer
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. £6000 to be refunded to Mrs. Leese for Herceptin treatmen
6. Wangaratta Community fundraising for Herceptin drug
7. Treatment of Breast Cancer with Herceptin for Nine Weeks
8. Herceptin is the cure for early stages of breast cancer?
9. 10-year-old Pleads, Herceptin For My Mum, Please
10. Norfolk PCTs To Offer Herceptin
11. Daughter Turns Saviour: Ailing Mother Provided Wonder Drug Herceptin, To Fight Cancer
Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: